

Research Article

LTB4 Promotes Acute Lung Injury via Upregulating the PLC ε -1/ TLR4/NF- κ B Pathway in One-Lung Ventilation

Jing Luo^(b),¹ Qingjie Ma^(b),² Heng Tang^(b),² Xi Zou^(b),² Xin Guo^(b),² Yuzhen Hu^(b),² Kejiang Zhou^(b),² and Rui Liu^(b)²

¹Department of Pain Management, The First People's Hospital of Yunnan Province, China ²Department of Anesthesiology, The First People's Hospital of Yunnan Province, China

Correspondence should be addressed to Rui Liu; 13888580754@163.com

Received 10 September 2021; Accepted 23 November 2021; Published 11 January 2022

Academic Editor: Taina K. Lajunen

Copyright © 2022 Jing Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Mechanical ventilation (MV) can provoke acute lung injury (ALI) by increasing inflammation activation and disrupting the barrier in lung tissues even causing death. However, the inflammation-related molecules and pathways in MV-induced ALI remain largely unknown. Hence, the purposes of this study are to examine the role and mechanism of a novel inflammation-related molecule, leukotriene B4 (LTB4), in ALI. *Methods.* The functions of LTB4 in one-lung ventilation (OLV) model were detected by the loss-of-function experiments. H&E staining was used to examine the pathologic changes of lung tissues. Functionally, PLCε-1 knockdown and Toll-like receptor 4 (TLR4)/NF-*κ*B pathway inhibitor were used to detect the regulatory effects of LTB4 on the phospholipase Cε (PLCε-1)/TLR4/nuclear factor-kappa B (NF-*κ*B) pathway. The levels of genes and proteins were determined by RT-qPCR and western blotting assay. The levels of inflammation cytokines and chemokines were measured by ELISA. *Results.* Here, we found LTA4H, leukotriene B (4) receptor 1 (BLT1), LTB4, and PLCε-1 upregulated in OLV rats and associated with inflammatory activation and lung permeability changes of lung tissues. For mechanism analyses, LTB4 promoted OLV-induced ALI by activating the PLCε-1/TLR4/NF-*κ*B pathway. *Conclusion.* LTB4 induced ALI in OLV rats by activating the PLCε-1/TLR4/NF-*κ*B pathway. Our findings might supply a new potential therapeutic for OLV-induced ALI.

1. Introduction

Acute lung injury (ALI) is a common acute respiratory distress syndrome (ARDS) mostly caused by supporting mechanical ventilation (MV) [1, 2]. ALI is the dominant cause of death induced by thoracic surgery [3]. The pathological changes include mechanical injury in the endotracheal wall and promote inflammatory activation in lung tissues. The mechanical injury of MV includes edemaflooded airways and unstable alveoli, which results in enhancing the permeability of pulmonary microvascular endothelial cells (PMVECs) and lung epithelial cells (LECs) [4, 5]. Usually, the damage of PMVECs and LECs has been induced by immune cell infiltrating. The inflammatory activity is mediated by the heavy increasing of neutrophils in lung tissues; the infiltrated neutrophils produce proinflammatory cytokines including interleukin-1 β (IL-1 β), IL-6, IL-8, and tumor necrosis factor- α (TNF- α) and attract chemokines such as C-X-C motif ligands (CXCLs) and C-C motif ligands (CCLs) [6]. On the one hand, neutrophils promote airway wall remodeling by excessing expression of matrix metalloproteinase-9 (MMP-9) and neutrophil elastase [7]. On the other hand, neutrophils recruit immune cells such as leukocytes and promote the adaptive immune responses [8]. Taken together, the above researches reveal that neutrophil plays a critical role in ALI through promoting proinflammatory cytokine production, chemokine attraction, and immune cell recruitment in lung tissues to affect the permeability of lung.

Leukotriene B4 (LTB4) is mostly secreted by neutrophils and enhances the recruitment of neutrophils during inflammatory activity [9]. The procedures of LTB4 generation include 5-lioxygenase (5-LO), which migrates to the nucleus and interacts with 5-LO activating protein (FLAP) to promote arachidonic acid (AA) generation by leukotriene A4 (LTA4), and then, LTB4 is generated from LTA4 hydrolyzed by LTA4 hydrolase (LTA4H) [10]. Previous studies indicate that LTB4 accelerates neutrophil trend and swims to the injury tissue sites [11, 12]. It also indicates that increasing LTB4 promotes acute pancreatitis-associated lung injury by inducing neutrophil transendothelial migration [13]. Previous studies indicate LTB4 acts a key role in ALI by interfering neutrophil behavior. However, the underlying mechanism of LTB4 in ALI is largely unknown.

Not only LTB4 but also phospholipase Cɛ (PLCɛ-1) acts a key role in neutrophil-mediated inflammation in ALI. Commonly, PLCE-1 is a member of the phospholipase (PLC) family and plays as a second messenger by generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [14]. The Ca²⁺ generation and protein kinase C (PKC) activation were further promoted by IP3 and DAG, respectively [15]. PLCE-1 mainly includes Ras association (RA) domain and guanine nucleotide exchange factor (EGF) domain, which is regulated by Ras family members and regulates the activity of small GTPase and Rap [16, 17]. It has been reported that PLCE promotes cell proliferation of renal cell carcinoma (RCC) by activating the nuclear factor-kappa B (NF- κ B) pathway [18]. In addition, PLC ε enhances tumorigenesis and process by inducing proinflammatory cytokine expression in colon epithelial cells via activating the NK-κB pathway [19]. The NF-*k*B pathway is a classic proinflammatory signaling pathway involved in the upregulation of cytokines, chemokines, and adhesion molecules during inflammation [20]. The system of NF- κ B is defined by the interaction between NF- κ B dimers, I κ B regulators, and IKK complexes. The main compounds of the NF- κ B family include RelA (p65), RelB, cRel, NF-kB1 (p105/p50), and NF- κ B2 (p100/p52), which are associated with homo- or heterodimerization and bind with DNA, respectively [21]. Increasing evidences have demonstrated that lipopolysaccharide (LPS) induced ALI by activating the NF- κ B pathway [22–24]. Despite larger researches indicating that the NF- κ B pathway may function a vital role in ALI, the regulatory mechanism of the NF- κ B pathway in ALI has not been clear.

Therefore, in this study, we examined the role of LTB4 and investigated the interaction between LTB4, PLC ε -1, and NF- κ B pathway in ALI. And we found that inhibition of LTB4 significantly reduced ALI by repressing the PLC ε -1/TLR4/NF- κ B pathway in one-lung ventilation (OLV) rat model.

2. Methods

2.1. Chemicals and Reagents. LTA4H inhibitor bestatin (HY-B0134) and TLR4/NF- κ B pathway inhibitor okanin (HY-N6673) were purchased from MedChemExpress (USA). Primary antibodies and secondary antibody goat anti-rabbit H&L were proved by Abcam (CA, USA).

2.2. Construction of OLV Rat Model. A total of thirty-six six-week-old male Sprague-Dawley (SD) rats with 200-220 g bodyweight were randomly divided into six groups

TABLE 1: The sequence primers in this study.

Gene symbol	Sequence (5'-3')
LTA4H	Forwards, 5'-CAGAGCCATGCCCGAGATAG-3'
	Reverse, 5 $'$ -GCAAATGTGGCGTTCCAAGT-3 $'$
BLT1	Forwards, 5 $^\prime$ -GTACCGCACAGTAACACCCA-3 $^\prime$
	Reverse, 5'-AGTCATGAAGCTGTCGGTGG-3'
PLCE-1	Forwards, $5'$ -GTGCGGCTGACACTCTGTAA-3'
	Reverse, 5 ['] -CCAGCGTCCTTGAGTTGCTA-3 [']
GAPDH	Forwards, 5 $^\prime$ -AATGGGCAGCCGTTAGGAAA-3 $^\prime$
	Reverse, $5'$ -GCGCCCAATACGACCAAATC- $3'$

(n = 6/group). One-lung ventilation (OLV) model was constructed according to the description of previous study [25]. Briefly, rats were anesthetized via intraperitoneally injecting 40 mg/kg pentobarbital. The trachea was exposed and placed with an endotracheal tube with inner diameter 3 mm, and then, the rats were connected to a ventilator (Harvard Apparatus, USA) with 3h right lung mechanical ventilation. The parameters of the ventilator were set as follows: tidal volume (VT) = 10 mL/kg, inspiration expiration (I : E) ratio = 1 : 1, inspired oxygen concentration (FiO_2) , 100%. Respiratory rate (RR) = 40 times/min. 0.5% sodium pentobarbital with a rate of 4 mL/kg/h was used for maintenance anesthesia. Rats were randomly divided into six groups, including control group, OLV group, OLV+bestatin group, OLV+sh-NC group, OLV+sh-PLCe-1 group, and OLV+okanin group. The rats of the bestatin group were treated following the described procedure before [26]. OLV +bestatin group rats intraperitoneally accepted 30 mg/kg bestatin at 15 min after surgery. OLV+okanin group rats accepted 50 mg/kg okanin at 15 min after surgery. OLV +sh-PLC ε -1 and OLV+sh-NC groups rats accepted 10 μ L shRNA (0.2 mg/mL) at 15 min after surgery. And the short hairpin RNA (shRNA) of PLCE-1 and its negative shRNA were designed and inserted into the pAd/BLOCK-iT[™]-DEST vector (Thermo Fisher, CA, USA) according to the manuscript instruction. All animal experiments in this study were approved by the Animal Care and Use Committee and the Ethics committee of the First People's Hospital of Yunnan Province (2017YY067).

2.3. Quantitative RT-PCR. Total RNA was extracted from the superior lobe of left lung tissues using a Trizol reagent (TaKaRa, China) according to the manufacturer's protocol. And the reverse DNA was amplified using a PrimeScriptTM 1st Strand cDNA Synthesis Kit (TaKaRa, China) following the manual of the manufacturer. And the quantitative PCR was performed using a TB Green[®] Fast qPCR Mix (TaKaRa, China) according to the manufacturer's instructions. The primers in this study are shown in Table 1. The relative expression of transcription was assessed using $2^{-\Delta\Delta Ct}$ methods. GAPDH was used as an internal control for gene expression.

2.4. Hematoxylin-Eosin (H&E) Staining. The part of the upper lobe of the right lung tissues was collected and fixed




FIGURE 1: Continued.




FIGURE 1: OLV induces inflammatory activation and lung permeability changes. (a, b) H&E staining detected the pathology of lung tissues in OLV and control rats. (c) The lung W/D ratio between OLV and control rats was calculated according to the formula [weight (wet) – weight (dry)]/weight (dry). (d) The PMN/WBC ratio of BALF in OLV and control rats was calculated. (e–k) ELISA performed to examine the levels of inflammation mediators (GM-CSF, IL-1 β , IL-8, KC, MCP-1, MIP-2, and TNF- α) between the OLV group and control rats. (l–o) Western blot detected the protein levels of Bcl-2, Bax, caspase 3, MLCK, VE-cadherin, occludin, and ZO-1 in OLV and control rats. **P* < 0.05, ***P* < 0.01, and ****P* < 0.001.

with 4% paraformaldehyde (PFA) and embedded with paraffin, and then, the tissues were sliced into 4 μ m and transferred onto glass slides. Furthermore, the slides were stained using an H&E staining kit (Beyotime, China) according to the manufacturer's protocol. And lung injury was calculated by injury scores based on the presence of atelectasis, hyaline membrane formation, neutrophil infiltration or aggregation into airspace, alveolar congestion, and hemorrhage: 0, minimal or no damage; 1, mild damage; 2, 25%-50% moderate damage; 3, 50%-75% severe damage; and 4, more than 75% maximal damage.

2.5. Lung Wet/Dry Ratio. The left lower lobes of lung tissues were harvested, and the weight was immediately measured. And then, the lung tissues were dehydrated in an incubator with 80° C for 72 h and the weight of the dry lung tissues was calculated. The wet/dry (W/D) ratio was evaluated according to [weight (wet) – weight (dry)]/weight (dry).

2.6. Enzyme-Linked Immunosorbent Assay (ELISA). The levels of GM-CSF, IL-1 β , IL-8, KC, MCP-1, MIP-2, TNF- α , and LTB4 in bronchoalveolar lavage fluid (BALF) or cell supernatants were measured by ELISA. Briefly, the part of the upper lobe of the right lung tissues was collected and homogenized with solution. The homogenates or cellcultured media were centrifuged, and the levels of supernatants, homogenates, or cell-cultured media were measured using the ELISA kit (Solarbio, China) following the manual of manufacturers. The sensitivity of GM-CSF (DY528, R&D, US, USA), IL-1 β (RLB00, R&D, US, USA), IL-8 (antibodies, Aachen, Germany), KC (RCN100, R&D, US, USA), MCP-1 (DY3144-05, R&D, US, USA), MIP-2 (RCN300, R&D, US, USA), TNF-α (DY510, R&D, US, USA), and LTB4 (520111, Cayman Chemicals, MI, USA) was 7.8 pg/ mL, 5 pg/mL, 31.25 pg/mL, 1.3 pg/mL, 7.8 pg/mL, 2.7 pg/ mL, 62.5 pg/mL, and 3.9 pg/mL.

2.7. Western Blotting Assay. Protein was isolated from the right lower lobe of lung tissues using a RIPA buffer (Beyotime, China) obeying the protocol of the manufacturer. Protein was then separated on 10% SDS-PAGE, transferred onto PVDF members (Millipore, USA), blocked with 5% nonfat milk, and probed with primary antibodies, such as PLCE-1 (ab109501, Abcam, USA), TLR4 (#14358, Cell Signaling Technology, USA), RelA (p65, #3039, Cell Signaling Technology, USA), caspase 3 (#9662, Cell Signaling Technology, USA), Bcl-2 (ab194583, Abcam, USA), Bax (ab32503, Abcam, USA), MLCK (ab76092, Abcam, USA), VEcadherin (ab231227, Abcam, USA), occludin (ab216327, Abcam, USA), ZO-1 (ab191143, Abcam, USA), and GAPDH (ab8245, Abcam, USA) at 4°C overnight, respectively. Subsequently, the members were incubated with the secondary antibody goat anti-rabbit IgG HRP (ab6721, Abcam, USA) at room temperature for 1 h. Finally, the bands were visualized using an enhanced chemiluminescent agent (Bio-Rad, USA). The levels of protein were normalized using GAPDH.

2.8. Identification of Inflammatory Cells in BALF. The number of PMNs and WBCs in BALF was assessed using a Diff-Quik staining assay according to the described procedure before [27]. Briefly, the BALF was centrifuged at 3000 rpm for 15 min and resuspended with $100 \,\mu$ L cold PBS. And the number of cells was counted using a hemocytometer. And the smears were made using cytocentrifugation (Thermo Fisher Scientific, USA) and visualized using Diff-Quik staining kit (Sysmex Co., Japan). At least 200 cells on each slide were calculated under a microscope according to the stained phenotype of macrophages, neutrophils, lymphocytes, and eosinophils.

2.9. Statistical Analysis. All values in this study were represented as mean \pm standard deviation (SD). And the statistical analysis was performed using GraphPad Prism 9.0. Differences between two groups or multiple groups were




FIGURE 2: Upregulation of LTB4 in OLV-induced ALI. (a, b) qRT-PCR validated expression of LTA4H and BLT1 in OLV and control rats. (c, d) Western blot was performed to examine expression of LTA4H and BLT1 in OLV and control rats. (e) ELISA examined LTB4 level in OLV and control rats. **P < 0.01 and ***P < 0.001.




FIGURE 3: Continued.

2.0 *** *** *** *** Relative protein levels 1.5 Olv Olv+Be Ctrl Bcl-2 1.0 Bax 0.5 Caspase 3 GAPDH 0.0 Bcl-2 Bax Caspase 3 Ctrl Olv Olv+Be (l) (m) 2.0 ** *** Ctrl Olv Olv+Be Relative protein levels 1.5 MLCK VE-cadherin 1.0 Occludin 0.5 ZO-1 GAPDH 0.0 VE-cadherin Occludin MLCK ZO-1 Ctrl Olv Olv+Be (n) (0)

FIGURE 3: Inhibiting LTB4 alleviates the OLV-induced ALI. (a, b) H&E staining examined the pathology of lung tissues in control, OLV, and bestatin-treated rats. (c) The lung W/D ratio of lung tissues in control, OLV, and bestatin-treated rats was calculated. (d) The PMN/WBC ratio of BALF in control, OLV, and bestatin-treated rats was detected. (e–k) ELISA performed to examine the levels of inflammation mediators (GM-CSF, IL-1 β , IL-8, KC, MCP-1, MIP-2, and TNF- α) in control, OLV, and bestatin-treated rats. (l–o) Western blot detected the protein levels of Bcl-2, Bax, caspase 3, MLCK, VE-cadherin, occludin, and ZO-1 in control, OLV, and bestatin-treated rats. *P < 0.05, **P < 0.01, and ***P < 0.001.

calculated using Student's *t*-test or one-way ANOVA. *P* value < 0.05 was identified as significant difference.

3. Results

3.1. OLV Induces Inflammatory Activation and Lung Permeability Changes. The OLV rat model was constructed, and H&E staining results revealed severe damage of lung tissues in OLV rats with obvious neutrophil infiltration into airspace, alveolar congestion, and hemorrhage compared with control rats (Figures 1(a) and 1(b)). The W/D ratio and the PMN/WBC ratio in BALF increased in OLV rats than control rats (Figures 1(c) and 1(d)), which indicated inflammation in OLV rats. Besides, the ELISA analyses showed increasing levels of cytokines and chemokines, including GM-CSF, IL-1 β , IL-8, KC, MCP-1, MIP-2, and TNF- α in BALF of OLV rats than control rats (Figures 1(e)–1(k)). Western blot results also showed that the expression of Bax,

caspase 3, MLCK, VE-cadherin, occludin, and ZO-1 was upregulated, and the expression of Bcl-2 was reduced in lung tissues from OLV rats (Figures 1(l)-1(o)). Our findings revealed that OLV induced acute lung injury by promoting inflammatory activation and pulmonary microvascular endothelial damage.

3.2. Upregulation of LTB4 in OLV-Induced ALI. LTB4 is generated from LTA4H and mediated by BLT1 to involve inflammation [28]. Here, we examined the expression of LTA4H, BLT1, and LTB4 in OLV rats. The qPCR and western blot results showed the mRNA and protein levels of LTA4H and BLT1 increased in lung tissues of OLV rats (Figures 2(a)-2(d)). ELISA results also indicated that increasing LTB4 level was observed in OLV rats (Figure 2(e)). These data indicated that LTB4 levels increased in OLV-induced ALI.






FIGURE 4: Inhibiting LTB4 reduces PLC ε -1 expression. (a–c) qRT-PCR validated expression of LTA4H, BLT1, and PLC ε -1 in control, OLV, and bestatin-treated rats. (d, e) Western blot was performed to examine expression of LTA4H, BLT1, and PLC ε -1 in control, OLV, and bestatin-treated rats. (f) ELISA examined LTB4 level in control, OLV, and bestatin-treated rats. **P* < 0.01 and ****P* < 0.001.


3.3. Inhibiting LTB4 Alleviates the OLV-Induced ALI. We further examined the role of LTB4 in OLV-induced rats by using bestatin, which is a potent inhibitor of LTA4H. As shown in Figures 3(a) and 3(b), H&E staining results indicated severe damage of lung tissue in OLV rats, whereas bestatin alleviated the damage of lung tissue compared with OLV rats. Bestatin also reduced W/D ratio and the PMN/WBC ratio in BALF of OLV rats (Figures 3(c) and 3(d)). The increasing levels of cytokines and chemokines in OLV rats were reduced by bestatin (Figures 3(e)–3(k)). We also observed bestatin reduced the protein levels of Bax, caspase 3, MLCK, VE-cadherin, occludin, and ZO-1, but increased


the protein levels of Bcl-2 in OLV rats (Figures 3(1)-3(0)). These data suggested that inhibition of LTB4 by bestatin alleviated the ALI in OLV rats.

3.4. Inhibiting LTB4 Reduces PLC ε -1 Expression. We deeply investigated the potential mechanism of LTB4 in OLV rats. qPCR and western blot results indicated that bestatin not only reduced the mRNA and protein levels of LTA4H and BLT1 (Figures 4(a)–4(e)) and the levels of LTB4 (Figure 4(f)) but also reduced the mRNA and protein levels of PLC ε -1 in OLV rats. Our findings suggested that inhibition of LTB4 by bestatin reduced PLC ε -1 expression in OLV rats.












FIGURE 5: Inhibition of the PLC ε -1/TLR4/NF-KB signaling pathway reduced OLV-induced ALI. (a, b) H&E staining examined the pathology of lung tissues in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats. (c) The lung W/D ratio of lung tissues in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats was calculated. (d) The PMN/WBC ratio of BALF in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats was detected. (e–k) ELISA performed to examine the levels of inflammation mediators (GM-CSF, IL-1 β , IL-8, KC, MCP-1, MIP-2, and TNF- α) in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats. (l–o) Western blot detected the protein levels of Bcl-2, Bax, caspase 3, MLCK, VE-cadherin, occludin, and ZO-1 in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats. *P < 0.05, **P < 0.01, and ***P < 0.001.

3.5. LTB4 Promotes OLV-Induced ALI by Activating the PLCε-1/TLR4/NF-κB Signaling Pathway. The TLR4/NF-κB signaling pathway is an important inflammatory pathway in lung injury [25, 29]. We detected whether LTB4 induced ALI in OLV rats by activating the PLC ε -1/TLR4/NF- κ B signaling pathway. Here, we found PLCE-1 knockdown or TLR4/NF- κ B pathway inhibitor okanin significantly alleviated the damage of lung tissues in OLV rats (Figures 5(a) and 5(b)). PLCE-1 knockdown or okanin also reduced the W/D ratio and the PMN/WBC ratio in BALF and the levels of cytokines and chemokines in OLV rats (Figures 5(c)-5(k)). PLCE-1 knockdown or okanin decreased the protein levels of Bax, caspase 3, MLCK, VE-cadherin, occludin, and ZO-1, but upregulated the protein levels of Bcl-2 in OLV rats (Figures 5(1)-5(0)). Furthermore, we also found PLCE-1 knockdown or okanin inhibited the mRNA and protein levels of LTA4H, BLT1, and PLCE-1 (Figures 6(a)-6(e)) and reduced the levels of LTB4 in OLV rats (Figure 6(f)). Additionally, the TLR4 level and phosphorylation of p65 remained inhibited by PLCE-1 knockdown or okanin

(Figures 6(g) and 6(h)). These data indicated that inactivating the PLC ϵ -1/TLR4/NF- κ B signaling pathway relieved the ALI in OLV rats.

4. Discussion

Mechanical ventilation (MV) is a common strategy for emergency treatment in clinics and causes ALI or ARDS. Mostly, ALI has characteristics with pulmonary hypoxaemia, edema, and inflammation [30]. The pathophysiology of ALI contains neutrophil recruitment, release of proinflammatory cytokines and chemokines, and permeability change of PMVECs and LECs [31]. Inflammatory activity seriously promotes the process of ALI. Moreover, LTB4 has been found to be involved in the upregulation of ALI and is associated with neutrophil migration to lung tissues [32]. However, there is little known about the underlying mechanism of LTB4 regulating inflammatory activity in ALI. Therefore, we deeply explored the regulatory effect of LTB4 and its mechanism in ALI.




FIGURE 6: Continued.




FIGURE 6: LTB4 promotes OLV-induced ALI by activating the PLC ε -1/TLR4/NF-KB signaling pathway. (a-c) qRT-PCR validated expression of LTA4H, BLT1, and PLC ε -1 in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats. (d, e) Western blot examined expression of LTA4H, BLT1, and PLC ε -1 in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats. (f) ELISA examined LTB4 level in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats. (g, h) Western blot detected expression of TLR4, P65, and phosphorylation of P65 in control rats, OLV rats, PLC ε -1 knockdown rats, and okanin-treated rats. (rats, *P < 0.05, **P < 0.01, and ***P < 0.001.

In the present study, we found LTB4 was upregulated in OLV rat model and promoted neutrophil and leukocyte recruitment to lung tissue, release of proinflammatory cytokines (TNF- α , IL-1 β , and IL-8) and chemokines (CXCL1, MCP-1, and MIP-2) and GM-CSF, and induction of lung permeability via activating PLC ε -1/TLR4/NF- κ B cascaded signaling pathway.

LTB4 has been reported to function as an inflammatory promoter in neutrophil recruitment to lung sites, also affecting neutrophil migration and apoptosis in ALI [33]. Upregulation of LTB4 enhances cytokine and chemokine activation and recruitment of neutrophil to focus of inflammation [34]. In addition, LTB4 induces immune cell infiltration, such as monocytes (macrophages) and eosinophils (NK cells, T cells, T8 cells, and T4 cells) that generate the production of IL-1, IL-6, IL-8, and TNF- α to prolong inflammation in lung tissues [35]. Our results confirmed that the previous researches reveal LTB4 accelerates inflammatory activity through recruiting neutrophils and promoting cytokine and chemokine release. It is known to us that PLC- ε acts a proinflammatory role in ALI by inducing PMVEC permeability change and barrier disruption by activating proinflammatory cytokines and chemokines of neutrophils [14]. Previous studies have demonstrated that LTB4 recruits and activates of neutrophils, monocytes, and eosinophils by activating PLC [36, 37]. However, the interaction between LTB4 and PLC- ε in ALI has been unknown. In this study, we firstly proved the correlation between LTB4 and PLC- ε in ALI by activating neutrophils.

CXCL8 (IL-8) activation acts a vital role in the accumulation of neutrophils in the PMVECs of the lung tissue [38]. Furthermore, CXCL8 was increased in leucocyte in acute and chronic inflammatory diseases [39]. It also reports that CXCL8 generated from pulmonary epithelial cells functions an important role in the inflammation [40]. In this study, we found an accumulation of CXCL8 in BALF. Previous research has indicated that CXCL8 is involved in acute inflammatory disease by regulating the NF- κ B pathway [41]. Besides, CXCL8 induces lung inflammation in asthma by activating the NF- κ B pathway [42]. In our study, we proved that release of CXCL8 enhanced NF- κ B pathway activity. TLR4 is a receptor for LPS, which acts a vital role in innate and adaptive immune responses [43]. It also plays a key role in cellular stress and immune response in ALI by activating the NF- κ B pathway and releasing the proinflammatory factors IL-1 β , IL-6, and TNF- α to further promote lung injury [23]. It has been demonstrated that inhibition of TLR4/NF- κ B pathway activation attenuates the inflammation in ALI [24].

5. Conclusion

Taken together, in this study, we explored a defined regulatory pathway which is the LTB4/PLC ε /CXCL8/TLR4/NF- κ B signaling pathway in ALI. Our findings might provide a novel potential therapeutic target for ALI and supply the novel insight to investigate neutrophil-mediated inflammatory diseases.

Data Availability

The methods and data generated and analyzed in this study are available from the corresponding author (Rui Liu) on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

Authors' Contributions

Rui Liu conceived and designed the experiments and corrected the manuscript. Jing Luo and Qingjie Ma performed the experiments and wrote the manuscript. Heng Tang and Xi Zou analyzed data in this study. Xin Guo, Yuzhen Hu, and Kejiang Zhou contributed reagents, materials, and analysis tools. Jing Luo and Qingjie Ma contributed equally to this work.

Acknowledgments

The study was supported by the National Natural Science Foundation of China (81760018), the Academician Expert Workstation of Yunnan Province (202005AF150033), and the First People's Hospital of Yunnan Province, Yunnan Province Clinical Research Center for Gynecological and Obstetric Disease (2022YJZX-FC22).

References

- Y. Butt, A. Kurdowska, and T. C. Allen, "Acute lung injury: a clinical and molecular review," *Archives of Pathology & Laboratory Medicine*, vol. 140, no. 4, pp. 345–350, 2016.
- [2] A. S. Slutsky, "History of mechanical ventilation. From Vesalius to ventilator-induced lung injury," *American Journal of Respiratory and Critical Care Medicine*, vol. 191, no. 10, pp. 1106–1115, 2015.
- [3] N. T. Mowery, W. T. H. Terzian, and A. C. Nelson, "Acute lung injury," *Current Problems in Surgery*, vol. 57, no. 5, p. 100777, 2020.
- [4] G. F. Nieman, P. Andrews, J. Satalin et al., "Acute lung injury: how to stabilize a broken lung," *Critical Care*, vol. 22, no. 1, p. 136, 2018.
- [5] G. F. Nieman, L. A. Gatto, and N. M. Habashi, "Impact of mechanical ventilation on the pathophysiology of progressive acute lung injury," *Journal of Applied Physiology*, vol. 119, no. 11, pp. 1245–1261, 2015.
- [6] B. T. Thompson, R. C. Chambers, and K. D. Liu, "Acute respiratory distress syndrome," *The New England Journal of Medicine*, vol. 377, no. 6, pp. 562–572, 2017.
- [7] P. L. Bruijnzeel, M. Uddin, and L. Koenderman, "Targeting neutrophilic inflammation in severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype?," *Journal* of Leukocyte Biology, vol. 98, no. 4, pp. 549–556, 2015.
- [8] J. G. Jayne, T. J. Bensman, J. B. Schaal et al., "Rhesus θ-defensin-1 attenuates endotoxin-induced acute lung injury by inhibiting proinflammatory cytokines and neutrophil recruitment," *American Journal of Respiratory Cell and Molecular Biology*, vol. 58, no. 3, pp. 310–319, 2018.
- [9] F. Sasaki, T. Koga, M. Ohba et al., "Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models," *JCI Insight*, vol. 3, no. 18, 2018.
- [10] R. Majumdar, A. Tavakoli Tameh, and C. A. Parent, "Exosomes mediate LTB4 release during neutrophil chemotaxis," *PLoS Biology*, vol. 14, no. 1, p. e1002336, 2016.
- [11] R. C. Chou, N. D. Kim, C. D. Sadik et al., "Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis," *Immunity*, vol. 33, no. 2, pp. 266–278, 2010.

- [12] B. McDonald and P. Kubes, "Chemokines: sirens of neutrophil recruitment-but is it just one song?," *Immunity*, vol. 33, no. 2, pp. 148-149, 2010.
- [13] B. Li, X. Han, X. Ye et al., "Substance P-regulated leukotriene B4 production promotes acute pancreatitis-associated lung injury through neutrophil reverse migration," *International Immunopharmacology*, vol. 57, pp. 147–156, 2018.
- [14] K. Umezawa, T. Nagano, K. Kobayashi et al., "Phospholipase Ce plays a crucial role in neutrophilic inflammation accompanying acute lung injury through augmentation of CXC chemokine production from alveolar epithelial cells," *Respiratory Research*, vol. 20, no. 1, p. 9, 2019.
- [15] K. M. Bijli, F. Fazal, S. A. Slavin et al., "Phospholipase C-ε signaling mediates endothelial cell inflammation and barrier disruption in acute lung injury," *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 311, no. 2, pp. L517–L524, 2016.
- [16] G. G. Kelley, S. E. Reks, J. M. Ondrako, and A. V. Smrcka, "Phospholipase C(epsilon): a novel Ras effector," *The EMBO Journal*, vol. 20, no. 4, pp. 743–754, 2001.
- [17] T. D. Bunney and M. Katan, "Phospholipase C epsilon: linking second messengers and small GTPases," *Trends in Cell Biology*, vol. 16, no. 12, pp. 640–648, 2006.
- [18] H. F. Du, L. P. Ou, X. D. Song et al., "Nuclear factor-κB signaling pathway is involved in phospholipase Cε-regulated proliferation in human renal cell carcinoma cells," *Molecular and Cellular Biochemistry*, vol. 389, no. 1-2, pp. 265– 275, 2014.
- [19] M. Wakita, H. Edamatsu, M. Li, A. Emi, S. Kitazawa, and T. Kataoka, "Phospholipase C∈ Activates Nuclear Factor-κB Signaling by Causing Cytoplasmic Localization of Ribosomal S6 Kinase and Facilitating Its Phosphorylation of Inhibitor κB in Colon Epithelial Cells," *The Journal of Biological Chemistry*, vol. 291, no. 24, pp. 12586–12600, 2016.
- [20] T. Lawrence, "The nuclear factor NF-kappaB pathway in inflammation," *Cold Spring Harbor Perspectives in Biology*, vol. 1, no. 6, 2009.
- [21] M. S. Hayden and S. Ghosh, "Shared principles in NF-kappaB signaling," *Cell*, vol. 132, no. 3, pp. 344–362, 2008.
- [22] L. Meng, L. Li, S. Lu et al., "The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways," *Molecular Immunology*, vol. 94, pp. 7–17, 2018.
- [23] J. X. Liu, X. Li, F. G. Yan et al., "Protective effect of forsythoside B against lipopolysaccharide-induced acute lung injury by attenuating the TLR4/NF-κB pathway," *International Immunopharmacology*, vol. 66, pp. 336–346, 2019.
- [24] C. Cao, C. Yin, S. Shou et al., "Ulinastatin protects against LPSinduced acute lung injury by attenuating TLR4/NF- κ B pathway activation and reducing inflammatory mediators," *Shock*, vol. 50, no. 5, pp. 595–605, 2018.
- [25] W. Z. Pan, J. Du, L. Y. Zhang, and J. H. Ma, "The roles of NFkB in the development of lung injury after one-lung ventilation," *European Review for Medical and Pharmacological Sciences*, vol. 22, no. 21, pp. 7414–7422, 2018.
- [26] X. Chen, N. Li, S. Wang et al., "Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin," *Journal of the National Cancer Institute*, vol. 95, no. 14, pp. 1053–1061, 2003.
- [27] J. Shen, J. Zhao, Q. Y. Ye, and X. D. Gu, "Interference of miR-943-3p with secreted frizzled-related proteins4 (SFRP4) in an

asthma mouse model," *Cell and Tissue Research*, vol. 378, no. 1, pp. 67–80, 2019.

- [28] K. Kato, T. Yokomizo, T. Izumi, and T. Shimizu, "Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene," *The Journal of Experimental Medicine*, vol. 192, no. 3, pp. 413–420, 2000.
- [29] J. Tang, L. Xu, Y. Zeng, and F. Gong, "Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NFkB signaling pathway," *International Immunopharmacology*, vol. 91, 2021.
- [30] A. A. Quartin, M. A. Campos, D. A. Maldonado, D. Ashkin, C. M. Cely, and R. M. Schein, "Acute lung injury outside of the ICU: incidence in respiratory isolation on a general ward," *Chest*, vol. 135, no. 2, pp. 261–268, 2009.
- [31] X. Wang, J. Yan, X. Xu et al., "Puerarin prevents LPS-induced acute lung injury via inhibiting inflammatory response," *Microbial Pathogenesis*, vol. 118, pp. 170–176, 2018.
- [32] Q. Xiao, N. Dong, X. Yao et al., "Bufexamac ameliorates LPSinduced acute lung injury in mice by targeting LTA4H," *Scientific Reports*, vol. 6, p. 25298, 2016.
- [33] X. Li, M. Xie, C. Lu et al., "Design and synthesis of leukotriene A4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury," *European Journal of Medicinal Chemistry*, vol. 203, p. 112614, 2020.
- [34] C. D. Sadik and A. D. Luster, "Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation," *Journal of Leukocyte Biology*, vol. 91, no. 2, pp. 207–215, 2012.
- [35] S. W. Crooks and R. A. Stockley, "Leukotriene B4," *The International Journal of Biochemistry & Cell Biology*, vol. 30, no. 2, pp. 173–178, 1998.
- [36] G. F. Mao, V. R. Vaidyula, S. P. Kunapuli, and A. K. Rao, "Lineage-specific defect in gene expression in human platelet phospholipase C-beta2 deficiency," *Blood*, vol. 99, no. 3, pp. 905– 911, 2002.
- [37] D. J. Meyers and R. S. Berk, "Characterization of phospholipase C from Pseudomonas aeruginosa as a potent inflammatory agent," *Infection and Immunity*, vol. 58, no. 3, pp. 659– 666, 1990.
- [38] Z. Bao, Q. Ye, W. Gong, Y. Xiang, and H. Wan, "Humanized monoclonal antibody against the chemokine CXCL-8 (IL-8) effectively prevents acute lung injury," *International Immunopharmacology*, vol. 10, no. 2, pp. 259–263, 2010.
- [39] B. Martínez-Burgo, S. L. Cobb, E. Pohl et al., "A C-terminal CXCL8 peptide based on chemokine-glycosaminoglycan interactions reduces neutrophil adhesion and migration during inflammation," *Immunology*, vol. 157, no. 2, pp. 173–184, 2019.
- [40] B. Li, C. Dong, G. Wang, H. Zheng, X. Wang, and C. Bai, "Pulmonary epithelial CCR3 promotes LPS-induced lung inflammation by mediating release of IL-8," *Journal of Cellular Physiology*, vol. 226, no. 9, pp. 2398–2405, 2011.
- [41] H. Lv, J. Li, and Y. Q. Che, "CXCL8 gene silencing promotes neuroglial cells activation while inhibiting neuroinflammation through the PI3K/Akt/NF-κB-signaling pathway in mice with ischemic stroke," *Journal of Cellular Physiology*, vol. 234, no. 5, pp. 7341–7355, 2019.

- [42] C. H. Lin, C. H. Shih, and B. C. Chen, "Thrombin-induced IL-8/CXCL8 release is mediated by CK2, MSK1, and NF-κB pathways in human lung epithelial cells," *European Journal of Pharmacology*, vol. 767, pp. 135–143, 2015.
- [43] B. B. Xue, B. H. Chen, Y. N. Tang, C. W. Weng, and L. N. Lin, "Dexmedetomidine protects against lung injury induced by limb ischemia-reperfusion via the TLR4/MyD88/NF-κB pathway," *The Kaohsiung Journal of Medical Sciences*, vol. 35, no. 11, pp. 672–678, 2019.